Oishi Y, Fu Z W, Ohnuki Y, Kato H, Noguchi T
Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, Tokyo University, Yayoi 1-1-1, Bunkyo-ku, Tokyo 113-8657, Japan.
Br J Dermatol. 2002 Nov;147(5):859-68. doi: 10.1046/j.1365-2133.2002.04949.x.
Glucocorticoids are widely used for the treatment of various diseases, despite known side-effects such as skin atrophy. Many studies have shown that the status of collagen fibres in the skin is affected by glucocorticoid treatment. However, the molecular mechanism underlying the alteration of collagen metabolism in the skin by glucocorticoid treatment remains unknown.
To characterize the molecular mechanisms related to the deterioration of the dermis in response to glucocorticoids, the status of two major types of collagen, collagenase, and tissue inhibitors of metalloproteinases (TIMPs) in the dorsal skin of rats was studied at the protein and mRNA levels.
Samples of rat dorsal skin were obtained after daily (1 mg kg-1) subcutaneous injections of dexamethasone (DEX) for 8 days. mRNA levels of two types of collagen and of TIMPs were measured by a lysate RNase protection assay. mRNA levels of collagenase were measured by a quantitative polymerase chain reaction. Protein levels of collagen and collagenase were measured by an immunoblot analysis.
Levels of type I tropocollagen and type III tropocollagen were drastically reduced in response to DEX. The effects of DEX treatment were more severe on type III than type I collagen: it also produced a significant decrease in fibril collagen of type III collagen. DEX treatment was found to decrease both active and latent forms of collagenase as well as its mRNA levels. Among TIMPs, mRNA levels of TIMP-1 and TIMP-2 were decreased in response to DEX treatment, whereas those of TIMP-3 were not affected.
These results suggest that DEX treatment strongly interferes with both the synthesis and degradation of type I collagen and, more drastically, type III collagen, the molecule that is known to play a major role in the initiation of wound healing. The present study may provide a molecular basis for the deterioration of skin function, impaired wound healing, and skin atrophy caused by glucocorticoid treatment.
尽管已知糖皮质激素有诸如皮肤萎缩等副作用,但仍被广泛用于治疗各种疾病。许多研究表明,糖皮质激素治疗会影响皮肤中胶原纤维的状态。然而,糖皮质激素治疗导致皮肤胶原代谢改变的分子机制仍不清楚。
为了阐明糖皮质激素引起真皮退变的分子机制,研究了大鼠背部皮肤中两种主要类型的胶原蛋白、胶原酶和金属蛋白酶组织抑制剂(TIMPs)在蛋白质和mRNA水平的状态。
每天(1mg/kg-1)皮下注射地塞米松(DEX)8天后获取大鼠背部皮肤样本。通过裂解物核糖核酸酶保护试验测量两种胶原蛋白和TIMPs的mRNA水平。通过定量聚合酶链反应测量胶原酶的mRNA水平。通过免疫印迹分析测量胶原蛋白和胶原酶的蛋白质水平。
DEX处理后,I型原胶原和III型原胶原水平急剧降低。DEX处理对III型胶原的影响比对I型胶原更严重:它还导致III型胶原的纤维状胶原显著减少。发现DEX处理可降低胶原酶的活性和潜伏形式及其mRNA水平。在TIMPs中,DEX处理后TIMP-1和TIMP-2的mRNA水平降低,而TIMP-3的mRNA水平未受影响。
这些结果表明,DEX处理强烈干扰I型胶原尤其是在伤口愈合起始中起主要作用的III型胶原的合成和降解。本研究可能为糖皮质激素治疗引起的皮肤功能恶化、伤口愈合受损和皮肤萎缩提供分子基础。